Back
Return
Biography

Dr. Tomoshige Kino

National Institutes of Health, USA

Head, Staff Scientist

E-mail: kinot@cc1.nichd.nih.gov

Qualifications

1994 Ph.D., Medical Science, The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan
1989-1992 Research Fellow, The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan
1985-1987 Residency, The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan
1985 Bachelor of Medicine, Chiba University Medical School, Chiba, Japan

Publications (Selected)

  1. Kino T., Yoshida S., Takahashi H., and Nishikawa T. Clinical features of Graves' disease. Journal of Asahi General Hospital 11: 34-37, 1990. (Japanese)
  2. Kino T., Yoshida S., Nakamura K., and Nishikawa T. Nonfunctioning adrenal tumors. Journal of Asahi General Hospital 11: 38-41, 1990. (Japanese)
  3. Kino T., Nishikawa T., Tamura Y., and Yoshida S. Clinical features of patients with isolated ACTH deficiency. Endocrinology in Clinical Medicine 17: 27-30, 1991. (Japanese)
  4. Oe K. and Kino T. A case of cytophagic histiocytic panniculitis. Journal of Japanese Reticuloendothelial Society 31: 13-20, 1991. (Japanese)
  5. Ban T., Hirai A., Kino T., Oeda T., Fujiki Y., Tamura Y., and Yoshida S. Sterol carrier protein 2 (SCP2)-like protein in rat aorta. Artery 18: 54-70, 1991.
  6. Nishikawa T., Yoshida A., Kino T., and Tamura Y.. Effect of AVP on the regulation of ACTH production by CRH. ACTH Related Peptides 3. 11-13, 1992. (Japanese)
  7. Kino T., Nishikawa T., Tamura Y., and Yoshida S. Important roles of pituitary antibodies in the pathophysiology in isolated ACTH deficiency. ACTH Related Peptides 3. 54-57, 1992. (Japanese)
  8. Omura M., Nishikawa T., Iizuka T., Kino T., Yoshida A., Saito H., Tamura Y., and Yoshida S. Studies on serum levels of androstenedione, dehydroepiandrosterone and dehydroepiandrosterone sulfate in healthy aging subjects and in patients with adrenocortical disease. Progress in Clinical Biochemistry 645-647,1992.
  9. Terano T, Fujii R, Kino T, Saitoh J, Tamura Y, Yoshida S, and Saeki N. A case of silent corticotropic adenoma. ACTH Related Peptides 4: 169-174,1993. (Japanese)
  10. Seya A., Terano T., Hattori Y., Tomizuka T., Morio H., Kino T., Hirai A., Nishikawa T., Tamura Y., and Yoshida S. Malignant exophthalmos associated with multiple myeloma. Internal Medicine 32: 1993.
  11. Tokinaga K., Hirai A., Kino T., Tamura Y., and Yoshida S. Increase in the content of sterol carrier protein 2 (SCP2) during foam cell formation of rat peritoneal macrophages. Ann NY Acad Sci 17: 571-574, 1995.
  12. Hirai A., Kino T., Tokinaga K., Tahara K., Tamura Y., and Yoshida S. Regulation of sterol carrier protein 2 (SCP2) gene expression in rat peritoneal macrophages during foam cell formation. A key role for free cholesterol content. J Clin Invest 94: 2215-2223, 1994.
  13. Kino T.. Changes of sterol carrier protein 2 (SCP2) during foam cell formation of rat peritoneal macrophages induced by acetylated LDL. Chiba Medical Journal 23: 533-540, 1994. (Japanese)
  14. Karl, M., Lamberts S.W.J., Koper J.W., Katz D.A., Huizenga N.E., Kino T., Haddad B.R., Hughes M.R., and Chrousos G.P. Cushing’s disease preceded by generalized glucocorticoid resistance: Clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assn Amer Phys 108: 296-307, 1996.
  15. De Castro M., Elliot S., Kino T., Bamberger C., Karl M., Webster E. and Chrousos G.P. The nonligand-binding ß-isoform of the human glucocorticoid receptor (hGRb): Tissue levels, mechanism of action and potential physiologic role. Mol Med 2:597-607, 1996.
  16. Kato K., Nobori M., Miyauchi Y., Ohnishi M., Yoshida S., Oya S., and Kino T. Pituitary apoplexy after subtotal thyroidectomy in an acromegalic patient with a large goiter. Internal Medicine 35: 472-477, 1996.
  17. Ramayya M., Zhou J., Kino T., Segars J.H., Bondy C.A. and Chrousos G.P. Steroidogenic factor 1 messenger ribonucleic acid expression in steroidogenic and nonsteroidogenic human tissues: Northern blot and in situ hybridization studies. J Clin Endocrinol Metab 82: 1799-1806, 1997.
  18. Gragerov A., Kino T., Iilina-Gragerova G., Chrousos G.P., Pavlakis G.N, HHR23A, the human homologue of the yeast repair protein RAD23 interacts specifically with Vpr protein and prevents cell cycle arrest but not the transcriptional effects of Vpr. Virology 245: 323-330, 1998.
  19. Kino T., Gragerov A., Kopp J.B., Stauber R.H., Pavlakis G.N., and Chrousos G.P. Human immunodeficiency virus type-1 Vpr is a glucocorticoid receptor coactivator. J Exp Med 189: 51-61, 1999.
  20. Kino T., Nordeen S. K., Chrousos G. P. Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP). J Steroid Biochem Mol Biol 70: 15-25, 1999.
  21. Yanovski J., Miller K. D., Kino T, Friedman T. C., Chrousos G. P., Tsigos C., and Falloon J., Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 84: 1925-1931, 1999.
  22. Link A., Kino T., Worth J. A., McGuire J.L, Crane M. L., Chrousos G. P., Wilder R. L. and Elenkov I. J., Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 164: 436-442, 2000.
  23. Kino T., Kopp, J. B. and Chrousos G. P., Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: Direct protective effects at variance with clinical phenomenology. J Steroid Biochem Mol Biol 75: 283-290, 2000.
  24. Longi C. A, Vottero A., Adamson P. C., Cole D. E., Kino T., Monte O., Chrousos G. P., Low glucocorticoid receptor a/b ratio in T-cell lymphoblastic leukemia. Horm Metab Res. 32:401-406, 2000.
  25. Kino T., Stauber, R. H., Resau, J. H., Pavlakis G. N. and Chrousos G. P. Pathologic human glucocorticoid receptor (GR) mutant has a transdominant negative effect on the wild type GR by inhibiting its translocation into the nucleus: Importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab. 86: 5600-5608, 2001.